Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2893441 | Atherosclerosis | 2009 | 5 Pages |
Abstract
In STEMI patients undergoing primary PCI, IC bolus administration of abciximab was associated with a larger reduction in sCD40L levels compared to standard IV bolus. Whether this more powerful anti-inflammatory effect of IC abciximab translates into improved clinical outcomes deserves investigation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Pablo Avanzas, Francisco Bosa-Ojeda, Sima Samimi-Fard, Francisco Marrero-Rodriguez, Juan Carlos Kaski,